Abstract: ObjectiveTo assess the feasibility and applicability of roche diagnostics MPX V2.0 in screening of blood nucleic acid technology(NAT) by its comparison with MPX V1.0. MethodsMPX V1.0 or MPX V2.0 reagent was used for NAT screening according to 9 418 ELISA-negative donors(HBsAg-,anti-HCV-, anti-HIV- and TP-). NAT positive samples were confirmed with electrochemical luminescence detection. Results8 samples were positive in 9 418 donors, in which 6 samples were observed MPX V1.0 positive and 6 , MPX V2.0 positive. We found one sample with low CT（MPX V1.0 CT=16.4,MPX V2.0 CT=18）and positive HCV-Ag (MPX V2.0). We believed that this donor was in the window phase of HCV infection confirmed by the second test one month later. ConclusionEither MPX V1.0 or MPX V2.0 reagent may miss low viral load samples (<20IU/mL). The sensitivity needs to be improved. MPX V2.0 can directly distinguish the type of viral infection based on fluorescence. MPX V2.0 is advantageous over MPX V1.0 to explain the positive donors and make early diagnosis.

Key words: Blood, Security, Nucleic, acid, technology, Blood, screening, MPX, V2.0